Posted: 30th March 2021
At least one-quarter the number of participants sought for SVI’s type 1 diabetes clinical trial have signed up since the trial’s launch last November. Pictured here is Lucy, the first participant enrolled in the BANDIT (baricitinib in new onset type 1 diabetes) trial.
Lucy is participating through the Royal Melbourne Hospital.
“I’m happy to participate in this trial to help researchers find ways to treat people with type 1 diabetes in the future. It has also been really helpful to have access to closer monitoring and support through the clinical trial team in the early stages of my diagnosis.”
The trial is investigating whether baricitinib, a drug used to treat rheumatoid arthritis, could protect insulin-producing cells from immune attack. This would allow individuals like Lucy to be able to produce insulin for a longer period of time and improve their glucose levels.
The two-year trial will monitor individuals aged 12-30 who have been diagnosed with the disease in the past 100 days.
In addition to The Royal Melbourne site, the trial is being undertaken at The Royal Children’s Hospital (Melbourne) and St Vincent’s Hospital (Melbourne) – and at one site in Adelaide, the Women’s and Children’s Hospital.
For more information visit the trial website.